Verrica Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Verrica Pharmaceuticals Inc. (VRCA) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-76.58-67.00-24.49-35.08-42.69-28.21-20.65
Depreciation & Amortization1.270.810.720.470.23-0.810.02
Stock Based Compensation7.1614.384.996.059.820.000.00
Change in Working Capital2.03-1.07-1.80-0.541.64-1.570.94
Change in Accounts Receivable4.34-3.93-0.490.000.000.000.00
Change in Accounts Payable-0.572.20-0.340.50-0.840.000.00
Change in Other Working Capital-1.740.81-0.981.441.970.000.00
Other Operating Activities5.1926.121.831.440.943.180.00
Net Cash from Operating Activities-60.93-38.58-18.65-27.58-30.21-27.41-17.87
Investing Activities
Capital Expenditures-0.030.36-0.30-0.88-1.470.68-0.77
Purchases of Investments0.000.0054.52-68.91-1.890.000.00
Sales/Maturities of Investments0.000.0054.3469.00-2.1126.64-79.12
Other Investing Activities0.010.00-0.18-0.20-0.22-1.220.00
Net Cash from Investing Activities-0.02-0.3654.04-1.00-3.5825.96-79.89
Financing Activities
Debt Repayment-2.06-0.02-0.020.00-0.090.000.00
Common Stock Issued39.6430.3026.9028.120.450.00107.25
Other Financing Activities0.16-0.18-0.020.000.320.00-7.88
Net Cash from Financing Activities37.7374.21-16.8733.6535.230.4299.38
Summary
Net Change in Cash-23.2235.2718.525.071.45-1.031.61
Cash at Beginning of Period69.5534.2715.7510.699.2410.278.66
Cash at End of Period46.3335.2434.2715.7510.699.2410.27
Free Cash Flow-60.95-38.94-18.95-28.47-31.68-28.09-18.65
Supplemental Disclosures
Interest Paid7.233.151.792.851.880.000.00